BMAA also appears to induce an increase of several neurodegenerative-disease biomarkers, such as the hyperphosphorylated Tau protein and the presence of neurofibrillary plaques (Parkinson syndrome) or the aggregated form of TDP-43 (ALS). The gene discussed is MAPT; the disease is amyotrophic lateral sclerosis.